Opyl Management

Management criteria checks 1/4

Opyl's CEO is Saurabh Jain, appointed in Nov 2023, has a tenure of less than a year. directly owns 0.49% of the company’s shares, worth A$16.67K. The average tenure of the management team and the board of directors is 5.7 years and 2.3 years respectively.

Key information

Saurabh Jain

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.5%
Management average tenure	5.7yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

CEO

Saurabh Jain

less than a year

Tenure

Mr. Saurabh Jain serves as Executive Director of Opyl Limited since April 30, 2024. He serves as Interim CEO of Opyl Limited since November 24, 2023. He was Independent Non-Executive Director of Spacetalk...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mark Ziirsen	CFO & Executive Chairman	3.7yrs	AU$99.49k	0.42% A$ 14.1k
Damon Rasheed	CTO & Executive Director	no data	AU$46.86k	2.29% A$ 77.5k
Saurabh Jain	Interim CEO & Executive Director	less than a year	no data	0.49% A$ 16.7k
Shane Lewis	Vice President of Sales & Partnerships	7.7yrs	no data	no data
Scott Sorochak	Chief Revenue Officer	7yrs	no data	no data
David Lilja	Company Secretary	4.4yrs	no data	no data

5.7yrs

Average Tenure

Experienced Management: OPL's management team is seasoned and experienced (5.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Ziirsen	CFO & Executive Chairman	3.7yrs	AU$99.49k	0.42% A$ 14.1k
Damon Rasheed	CTO & Executive Director	5.3yrs	AU$46.86k	2.29% A$ 77.5k
Saurabh Jain	Interim CEO & Executive Director	less than a year	no data	0.49% A$ 16.7k
Mark Simari	Non-Executive Director	less than a year	no data	0.59% A$ 20.0k
Dimitrie Spiru Stephenson	Board Advisor	less than a year	no data	no data
Christopher Ciavarra	Member of Advisory board	5.9yrs	no data	no data
Antanas Guoga	Non-Executive Director	less than a year	no data	10.55% A$ 357.0k
Kirsten Daru	Member of Advisory Board	5.9yrs	no data	no data
Paul-Olivier DeHaye	Member of Advisory Board	no data	no data	no data
Ari Scharg	Member of Advisory Board	no data	no data	no data

2.3yrs

Average Tenure

50.5yo

Average Age

Experienced Board: OPL's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Opyl Management

Management criteria checks 1/4

Key information

Recent management updates

Opyl Limited, Annual General Meeting, May 27, 2024

Opyl Limited Appoints Saurabh Jain as Interim Chief Executive Officer

Opyl Limited, Annual General Meeting, Nov 29, 2023

Opyl Limited Announces Senior Leadership Changes

Opyl Limited Appoints Dr. Hugo Stephenson as Board Advisor

Opyl Limited Announces Resignation of Julian Chick as Non-Executive Director

Recent updates

Opyl Limited, Annual General Meeting, May 27, 2024

New major risk - Share price stability

Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million.

Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.576 million.

Opyl Limited Appoints Saurabh Jain as Interim Chief Executive Officer

Opyl Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.022 loss per share (vs AU$0.038 loss in FY 2022)

New minor risk - Financial data availability

Opyl Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

New major risk - Shareholder dilution

Opyl Limited Announces Senior Leadership Changes

Opyl Limited Appoints Dr. Hugo Stephenson as Board Advisor

Opyl Limited Announces Resignation of Julian Chick as Non-Executive Director

No independent directors

No independent directors

Opyl Limited, Annual General Meeting, Nov 28, 2022

Opyl Limited Announces ihat its Clinical Trial Prediction and Protocol Design Software Solution, Trialkey

Opyl Limited Announces ihat its Clinical Trial Prediction and Protocol Design Software Solution, Trialkey

Full year 2022 earnings released: AU$0.038 loss per share (vs AU$0.028 loss in FY 2021)

Opyl Limited Announces the Commencement of Two New Clinical Trial Recruitment Customer Projects Using Opin

Less than half of directors are independent

Full year 2021 earnings released: AU$0.028 loss per share (vs AU$0.025 loss in FY 2020)

Opyl Limited Announces Clinical Trial Recruitment Platform Opin Enters Global Strategic Alliance

Opyl Limited Introduces Opin - Match Patients to Clinical Trials

Opyl Limited announced that it expects to receive AUD 1.38 million in funding

Executive Director recently bought AU$701k worth of stock

Opyl Ltd Announces Management Changes

New 90-day high - AU$0.23

Full year earnings released - AU$0.068 loss per share

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age